Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 vaccine plus nivolumab and ipilimumab versus nivolumab and ipilimumab in first-line unresectable or metastatic melanoma
2019-002026-75Phase 2Terminated
- Sponsor
- Ultimovacs ASA
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing UV1 + nivolumab + ipilimumab with Nivolumab + ipilimumab (2 arms). Primary endpoint: Progression-free survival. Started Dec 2019; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-002026-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002026-75.